Sagimet Biosciences (STU:0O2) 3-Year Revenue Growth Rate: 0.00% (As of Mar. 2026)


STU:0O2 Sagimet Biosciences Inc STU:0O2
10 GF Score
Price €6.54
! 2 Warning Signs
View Full Analysis

What is Sagimet Biosciences 3-Year Revenue Growth Rate?

Sagimet Biosciences STU:0O2 -1.51% 10 3-Year Revenue Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 765 Biotechnology companies, Sagimet Biosciences ranks worse than 130718.82% on this metric.

Sagimet Biosciences's Revenue per Share for the three months ended in Mar. 2026 was €0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Sagimet Biosciences  (STU:0O2) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Sagimet Biosciences 3-Year Revenue Growth Rate Related Terms

STU:0O2 vs EDIT, AUTL, FBRX: 3-Year Revenue Growth Rate Comparison

For the Biotechnology subindustry, Sagimet Biosciences's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sagimet Biosciences 3-Year Revenue Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Sagimet Biosciences's 3-Year Revenue Growth Rate falls into.


STU:0O2
10GF Score
Sagimet Biosciences Inc STU:0O2
3-Year Revenue Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagimet Biosciences 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

What does a 3-Year Revenue Growth Rate of 0.00% mean?
Sagimet Biosciences (STU:0O2) has a 3-Year Revenue Growth Rate of 0.00% as of Mar. 2026. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Sagimet Biosciences and its competitors. According to the industry distribution chart, Sagimet Biosciences ranks #999999 out of 765 companies in the Biotechnology industry.
Is Sagimet Biosciences' 3-Year Revenue Growth Rate too high?
Sagimet Biosciences' current 3-Year Revenue Growth Rate is 0.00%. Based on the distribution chart, Sagimet Biosciences ranks #999999 out of 765 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' 3-Year Revenue Growth Rate compare to EDIT and AUTL?
According to the Biotechnology industry distribution chart, Sagimet Biosciences ranks #999999 out of 765 companies for 3-Year Revenue Growth Rate. This places Sagimet Biosciences in the lower half of its industry. The industry median 3-Year Revenue Growth Rate is 3.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Biotechnology company?
The median 3-Year Revenue Growth Rate among Biotechnology companies is 3.00, based on 765 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Sagimet Biosciences and its competitors. For the Biotechnology industry, the median 3-Year Revenue Growth Rate is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sagimet Biosciences's current 3-Year Revenue Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current 3-Year Revenue Growth Rate of 0.00%. The current 3-Year Revenue Growth Rate is 0.00%. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current 3-Year Revenue Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sagimet Biosciences Business Description

Other Exchanges SGMT:USA
Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score

Get the complete analysis for STU:0O2

3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.54
Price